# Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

> **NCT02350361** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Recombinant human endostatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02350361
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2015-07
- **Final completion:** 2016-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02350361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02350361, "Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02350361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*